Company intelligence / Profile preview

ECM Pharmacology

Warrendale, Pennsylvania, United Statesecm-congress.org ↗

Ownership: Private
Employees: ~9
Development stage: Commercial

Overview

The company has received FDA IDE approval to begin clinical trials of its lead product ECMT‑100 for treating anorectal fistulas—a non-surgical regenerative hydrogel therapy. Preclinical work supports broader applications in muscle and ocular tissue repair.

Therapeutic areas: GastroenterologyOphthalmologyOther
Modalities: Hydrogel-based drug delivery therapyBiologic (extracellular matrix-derived products)Matrix-bound nanovesicle therapy
Industry: Biotech

Partnerships

Exclusive worldwide rights from University of Pittsburgh/McGowan Institute for Regenerative Medicine for core patent portfolio.No major pharma partnerships disclosed as of June 2025.

Beyond the preview

Go deeper on ECM Pharmacology.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ECM Pharmacology.

Explore the full profile